ABSTRACT
The 2018 and 2019 guidelines from the American College of Cardiology and American Heart Association reflect the complexity of individualized cholesterol management. The documents address more detailed risk assessment, newer nonstatin cholesterol-lowering drugs, special attention to patient subgroups, and consideration of the value of therapy, all with the aim of creating personalized treatment plans for each patient. Overall, the guidelines recommend shared decision-making to meet the individual needs of each patient.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.
- Cara Reiter-Brennan
- Albert D. Osei, MD, MPH
- S. M. Iftekhar Uddin, MBBS, MSPH
- Olusola A. Orimoloye, MD, MPH
- Olufunmilayo H. Obisesan, MD, MPH
- Mohammadhassan Mirbolouk, MD
- Michael J. Blaha, MD, MPH
- Omar Dzaye, MD, PhD⇑
- Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Baltimore, MD
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD
- Department of Radiology and Neuroradiology, Charité, Berlin, Germany
- ADDRESS:
Omar Dzaye MD PhD, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Blalock 524, Baltimore, MD 21287; odzaye{at}jhmi.edu
ABSTRACT
The 2018 and 2019 guidelines from the American College of Cardiology and American Heart Association reflect the complexity of individualized cholesterol management. The documents address more detailed risk assessment, newer nonstatin cholesterol-lowering drugs, special attention to patient subgroups, and consideration of the value of therapy, all with the aim of creating personalized treatment plans for each patient. Overall, the guidelines recommend shared decision-making to meet the individual needs of each patient.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.